High Exposure to Perfluoroalkyl Substances and Antibody Responses to SARS-CoV-2 mRNA Vaccine—an Observational Study in Adults from Ronneby, Sweden

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,07 MB, PDF-dokument

  • Axel G. Andersson
  • Anna Lundgren
  • Yiyi Xu
  • Christel Nielsen
  • Christian H. Lindh
  • Daniela Pineda
  • Julia Cederlund
  • Elisavet Pataridou
  • Tøttenborg, Sandra Søgaard
  • Kajsa Ugelvig Petersen
  • Tony Fletcher
  • Martin Lagging
  • Mats Bemark
  • Kristina Jakobsson
  • Ying Li
Background:
Per- and polyfluoroalkyl substances (PFAS) are widely used, environmentally ubiquitous, and stable chemicals that have been associated with lower vaccine-induced antibody responses in children; however, data on adults are limited. The drinking water from one of the two waterworks in Ronneby, Sweden, was heavily contaminated for decades with PFAS from firefighting foams, primarily perfluorohexane sulfonic acid and perfluorooctanesulfonic acid (PFOS). Vaccination against SARS-CoV-2 offered a unique opportunity to investigate antibody responses to primary vaccination in adults who had been exposed to PFAS.

Objectives:
Our objective was to evaluate associations between PFAS, across a wide range of exposure levels, and antibody responses in adults 5 wk and 6 months after a two-dose vaccination regime against SARS-CoV-2.

Methods:
Adults age 20–60 y from Ronneby (lowercase italic n equals 309n=309
, median PFOS serum level 47 nanograms per milliliter47 ng/mL
, fifth to 95th percentile 4 to 213 nanograms per milliliter4–213 ng/mL
) and a group with background exposure (lowercase italic n equals 47n=47
, median PFOS serum level 4 nanograms per milliliter4 ng/mL
) received two doses of the Spikevax (Moderna) mRNA vaccine. The levels of seven PFAS were measured in serum before vaccination. Serum immunoglobulin G antibodies against the SARS-CoV-2 spike antigen (S-Abs) were measured before vaccination and at 5 wk (lowercase italic n equals 350n=350
) and 6 months (lowercase italic n equals 329n=329
) after the second vaccine dose. Linear regression analyses were fitted against current, historical, and prenatal exposure to PFAS, adjusting for sex, age, and smoking, excluding individuals with previous SARS-CoV-2-infection.

Results:
PFAS exposure, regardless of how it was estimated, was not negatively associated with antibody levels 5 wk [current PFOS: negative 0.5 percent−0.5%
S-Abs/PFOS interquartile range (IQR); 95% confidence interval (CI): negative 8−8
, 7] or 6 months (current PFOS: 3% S-Abs/PFOS IQR; 95% CI: negative 6−6
, 12) after COVID-19 vaccination.

Discussion:
Following a strict study protocol, rigorous study design, and few dropouts, we found no indication that PFAS exposure negatively affected antibody responses to COVID-19 mRNA vaccination for up to 6 months after vaccination. https://doi.org/10.1289/EHP11847
OriginalsprogEngelsk
Artikelnummer087007
TidsskriftEnvironmental Health Perspectives
Vol/bind131
Udgave nummer8
Antal sider11
ISSN0091-6765
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
The study was financed by grants from Interreg Öresund-Kattegat-Skagerrak (EXCOVER, ID NYPS 20303383) and FORTE (2016-00250, 2019-00601), and in-kind support from the University of Gothenburg and Lund University. EudraCT-number: 2021-000842-16.

Funding Information:
The authors would like to thank the participants, the personnel at the Kallinge primary health care unit, the study monitor, and Region Blekinge. In addition, the authors thank T. Bergström at the Serology lab at the Clinical Microbiology laboratory at the Sahlgrenska University Hospital, Gothenburg, Sweden, for organizing the antibody analyses. Conceptualization was conducted by A.A., A.L., M.B., K.J., and Y.L. Gathering of samples was organized by A.A., A.L., J.C., E.P., and K.J. Sample analyses was organized by C.L., D.P., and M.L. Data curation and formal analysis was conducted by A.A. and Y.L. Funding was acquired by C.L., S.S.T., K.U.P., M.L., and K.J. Writing of original draft was completed by A.A. and K.J. Reviewing and editing of drafts was done by all authors. All authors contributed intellectually. The study was financed by grants from Interreg Öresund-Kattegat-Skagerrak (EXCOVER, ID NYPS 20303383) and FORTE (2016-00250, 2019-00601), and in-kind support from the University of Gothenburg and Lund University. EudraCT-number: 2021-000842-16.

Publisher Copyright:
© 2023, Public Health Services, US Dept of Health and Human Services. All rights reserved.

ID: 371746060